<DOC>
	<DOCNO>NCT00028782</DOCNO>
	<brief_summary>This phase II trial study well EF5 work detect oxygen level blood vessel tumor cell patient undergo photodynamic therapy intraperitoneal pleural cancer . Diagnostic procedure use EF5 detect oxygen level blood vessel tumor cell may help improve way photodynamic therapy give</brief_summary>
	<brief_title>EF5 Detecting Oxygen Level Blood Vessels Tumor Cells Patients Undergoing Photodynamic Therapy Intraperitoneal Pleural Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine level hypoxia etanidazole derivative EF5 binding patient intraperitoneal pleural malignancy treat photodynamic therapy . II . Determine microvascular density patient population . III . Determine relationships level hypoxia , measure microvascular density , photosensitizer level patient population . IV . Correlate hypoxia photosensitizer level clinical outcome patient population . V. Determine toxic effect EF5 patient population . OUTLINE : This multicenter study . Patients receive etanidazole derivative EF5 IV 1-2 hour . Approximately 48 hour EF5 administration , patient intraperitoneal tumor undergo surgical resection . Patients pleural tumor undergo surgical resection approximately 24 hour EF5 administration . Tumors analyze EF5 bind microvascular density immunohistochemistry fluorescent antibody technique . Patients follow 2 week 30-45 day post EF5 infusion . PROJECTED ACCRUAL : A total 80 patient ( 50 intraperitoneal malignancy 30 pleural malignancy ) accrue study within 2.5 year . Patients stratified disease ( intraperitoneal malignancy v pleural malignancy ) .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etanidazole</mesh_term>
	<criteria>Histologically confirm intraperitoneal pleural malignancy Currently enrol 1 3 photodynamic therapy trial ( UPCC2997 , UPCC4997 , UPCC05503 ) Plan undergo surgery treatment one protocol Patients suspect recurrent disease undergo surgery diagnosis debulking allow frozen section show malignant disease No active extraabdominal metastatic disease and/or intrahepatic involvement secondary metastatic carcinoma No borderline tumor low malignant potential No abdominal disease debulked less 5 mm residual disease maximal dimension Performance status ECOG 02 WBC least 2,000/mm^3 Platelet count great 100,000/mm^3 Bilirubin less 1.5 mg/dL No severe liver disease No cirrhosis No grade III IV elevation liver function study Creatinine great upper limit normal Creatinine clearance least 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month completion study treatment Weight 130 kg HIV negative Able tolerate anesthesia major surgery No grade III IV peripheral neuropathy No regional enteritis ulcerative colitis No contraindication anesthesia major surgery Prior combination chemotherapy malignancy allow No concurrent chemotherapy except recurrent persistent disease No concurrent radiotherapy except recurrent persistent disease Prior surgery malignancy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>